RECORDATI RARE DISEASES ANNOUNCE PUBLICATION IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM OF THE PHASE III LINC 4 STUDY CONFIRMING EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN PATIENTS WITH CUSHING’S DISEASE 03/29/2022 Recordati completes the acquisition of EUSA Pharma (UK) 03/17/2022 Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 03/10/2022 Pagination First page « First Previous page ‹ Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next › Last page Last »
RECORDATI RARE DISEASES ANNOUNCE PUBLICATION IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM OF THE PHASE III LINC 4 STUDY CONFIRMING EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN PATIENTS WITH CUSHING’S DISEASE 03/29/2022
Shortage of US-labeled TRANXENE T-TAB® Tablets (clorazepate dipotassium tablets, USP) 7.5 mg 03/10/2022
